This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Advertisement
Advertisement
Preamble
This article discusses the clinical data for covalent BTK inhibitors in CLL in the front-line setting and considerations when choosing initial BTK inhibitor therapy. A future article that discusses noncovalent BTK...
A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.
In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.
Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.
A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.
Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.